Haleon: Perbedaan antara revisi

| predecessor = GSK Consumer Healthcare<br/>Pfizer Consumer Healthcare

* [[Dave Lewis (businessmanpengusaha)|Dave Lewis]] {{small|(Chairman)}}

| products = {{hlist|[[Higiene mulut]]|produk nutrisi|[[obat-obatan]]|produk nutrisi}}

| revenue ={{increase}} £10,858 juta (2022)<ref name="results">{{cite web |title=Annual results 2022|url=https://www.haleon.com/content/dam/cf-consumer-healthcare/bp-haleon/en_US/documents/investors/Haleon-FY-2022-Press-release-02-March-2023.pdf|publisher=Haleon|access-date=2 MarchMaret 2023|archive-date=2023-03-07|archive-url=https://web.archive.org/web/20230307063208/https://www.haleon.com/content/dam/cf-consumer-healthcare/bp-haleon/en_US/documents/investors/Haleon-FY-2022-Press-release-02-March-2023.pdf|dead-url=no}}</ref>

| num_employees = 22,000+ (2022)<ref>{{cite news |url=https://www.theguardian.com/business/2022/jul/18/gsk-haleon-begins-trading-listing-shares-market-value |title=GSK spin-off Haleon begins trading in biggest European listing in a decade |date=18 JulyJuli 2022 |work=[[The Guardian]] |first1=Mark |last1=Sweney |first2=Julia |last2=Kollewe |access-date=2023-08-12 |archive-date=2023-02-02 |archive-url=https://web.archive.org/web/20230202160535/https://www.theguardian.com/business/2022/jul/18/gsk-haleon-begins-trading-listing-shares-market-value |dead-url=no }}</ref>

'''Haleon plc''' adalah perusahaan kesehatan konsumen multinasional Inggris dengan kantor pusat di [[Jembatan jembatan|Weybridge]], [[Inggris]].<ref>{{Cite web|title=GSK announces independent Consumer Healthcare company is to be called Haleon {{!}} GSK|url=https://www.gsk.com/en-gb/media/press-releases/gsk-announces-independent-consumer-healthcare-company-is-to-be-called-haleon/|website=www.gsk.com|language=en-GB|access-date=21 Februari 2023|archive-date=2023-02-21|archive-url=https://web.archive.org/web/20230221203149/https://www.gsk.com/en-gb/media/press-releases/gsk-announces-independent-consumer-healthcare-company-is-to-be-called-haleon/|dead-url=no}}</ref> Perusahaan ini adalah salah satu bisnis perawatan kesehatan konsumen terbesar di dunia, dengan merek termasuk [[pasta gigi]] [[Sensodyne]], [[Analgesik|obat penghilang rasa sakit]] [[Parasetamol|Panadol]] dan [[Ibuprofen|Advil]] serta [[vitamin]] [[Centrum (multivitamin)|Centrum]].<ref>{{Cite news|last=Ralph|first=Alex|date=2 JulyJuli 2022|title=GlaxoSmithKline prepares to get back to basics with historic break-up|url=https://www.thetimes.co.uk/article/three-centuries-of-gsk-story-about-to-add-a-new-chapter-3jrbn8kkq|work=[[The Times]]|access-date=4 JulyJuli 2022|archive-date=2023-08-05|archive-url=https://web.archive.org/web/20230805105647/https://www.thetimes.co.uk/article/three-centuries-of-gsk-story-about-to-add-a-new-chapter-3jrbn8kkq|dead-url=no}}</ref> Perusahaan ini adalah pemimpin global dalam obat [[Penggolongan Obat|bebas]] dengan pangsa pasar 7,3 persen.<ref name="forbes1">{{Cite news|last=Cornell|first=Joe|date=15 JulyJuli 2021|title=GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022|url=https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0|work=[[Forbes]]|access-date=10 JuneJuni 2022|archive-date=2023-02-11|archive-url=https://web.archive.org/web/20230211180517/https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0|dead-url=no}}</ref>

Haleon didirikan pada 18 Juli 2022 sebagai [[spin-offpemisahan perusahaan]] dari [[GSK plc|GSK]].<ref>{{Cite web|title=Prospectus|url=https://www.gsk.com/media/7702/haleon-plc-prospectus.pdf|publisher=GSK plc|page=15|access-date=10 JuneJuni 2022|archive-date=2022-06-01|archive-url=https://web.archive.org/web/20220601125715/https://www.gsk.com/media/7702/haleon-plc-prospectus.pdf|dead-url=yes}}</ref>

Sir [[Dave Lewis (pengusaha)|David Lewis]] adalah [[ketua]], dengan Brian McNamara sebagai CEO.<ref name="haleonsky">{{Cite news|last=Kleinman|first=Mark|date=3 MayMei 2022|title=GSK's £45bn Panadol and Sensodyne-maker Haleon in talks to hire banks|url=https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875|work=[[Sky News]]|access-date=10 JuneJuni 2022|archive-date=2023-02-11|archive-url=https://web.archive.org/web/20230211180519/https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875|dead-url=no}}</ref> Haleon terdaftar di [[Bursa Efek London|London Stock Exchange]] dan merupakan komponen dari [[Indeks FTSE 100|FTSE 100]], dengan listing sekunder di [[Bursa Efek New York|New York Stock Exchange]] . Penjualan tahunan berjumlah sekitar £10 miliar di 120 pasar pada tahun 2020.<ref name="forbes12">{{Cite news|last=Cornell|first=Joe|date=15 July 2021|title=GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022|url=https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0|work=[[Forbes]]|access-date=10 JuneJuni 2022|archive-date=2023-02-11|archive-url=https://web.archive.org/web/20230211180517/https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0|dead-url=no}}</ref>

GSK dan [[Pfizer]] menggabungkan bisnis layanan kesehatan konsumen mereka pada tahun 2019.<ref name="cnn1">{{Cite news|last=Shane|first=Daniel|date=19 DecemberDesember 2018|title=Advil meet Excedrin: Pfizer and GSK are merging their consumer healthcare businesses|url=https://edition.cnn.com/2018/12/19/business/pfizer-gsk-healthcare/index.html|work=[[CNN]]|access-date=10 JuneJuni 2022|archive-date=2023-06-06|archive-url=https://web.archive.org/web/20230606095307/https://edition.cnn.com/2018/12/19/business/pfizer-gsk-healthcare/index.html|dead-url=no}}</ref> GSK memiliki lebih dari dua pertiga dari [[Perusahaan patungan|usaha patungan tersebut]], dan Pfizer memegang sisanya.<ref name="cnn1" />

GSK mengumumkan rencana untuk memisahkan Haleon pada tahun 2018, untuk memberikan "fokus ekstra dan daya tembak ekstra kepada pembuat obat yang lelah dengan mempersiapkan dan menghentikan divisi konsumen".<ref name="reuters1">{{Cite news|last=Donnellan|first=Aimee|date=9 JuneJuni 2022|title=GSK castoff starts life with target on its back|url=https://www.reuters.com/breakingviews/gsk-castoff-starts-life-with-target-its-back-2022-06-09/|work=[[Reuters]]|access-date=10 JuneJuni 2022|archive-date=2022-09-22|archive-url=https://web.archive.org/web/20220922114359/https://www.reuters.com/breakingviews/gsk-castoff-starts-life-with-target-its-back-2022-06-09/|dead-url=no}}</ref>

[[Unilever]] menawarkan £50 miliar untuk bisnis tersebut pada tahun 2022, dalam tawaran yang ditolak GSK.<ref name="guardian1">{{Cite news|last=Jolly|first=Jasper|date=19 JanuaryJanuari 2022|title=Unilever will not increase £50bn offer for GSK consumer arm|url=https://www.theguardian.com/business/2022/jan/19/unilever-will-not-increase-50bn-offer-for-gsk-consumer-arm|work=[[The Guardian]]|access-date=10 JuneJuni 2022|archive-date=2022-10-18|archive-url=https://web.archive.org/web/20221018002210/https://www.theguardian.com/business/2022/jan/19/unilever-will-not-increase-50bn-offer-for-gsk-consumer-arm|dead-url=no}}</ref> [[Nestlé]] mengkaji kemungkinan penawaran bersama dengan [[Reckitt Benckiser|Reckitt]].<ref name="bloomberg1">{{Cite news|date=25 MayMei 2022|title=Nestle Eyed Biggest-Ever Deal in Aborted Move for GSK Unit|url=https://www.bloomberg.com/news/articles/2022-05-25/nestle-eyed-biggest-ever-deal-in-aborted-move-for-gsk-consumer#xj4y7vzkg|work=[[Bloomberg News]]|access-date=10 JuneJuni 2022|archive-date=2023-04-30|archive-url=https://web.archive.org/web/20230430142405/https://www.bloomberg.com/news/articles/2022-05-25/nestle-eyed-biggest-ever-deal-in-aborted-move-for-gsk-consumer#xj4y7vzkg|dead-url=no}}</ref>

Usulan spin-off merek perawatan bibir [[ChapStick]] senilai $600 juta diperdebatkan pada tahun 2023.<ref name="bloomberg2">{{Cite news|last=Tse|first=Crystal|last2=Nair|first2=Dinesh|last3=David|first3=Ruth|date=24 FebruaryFebruari 2023|title=GSK Spinoff Haleon Explores Potential $600 Million Sale of ChapStick Brand|url=https://archive.phtoday/lPFZo20230224231835/https://www.bloomberg.com/news/articles/2023-02-24/gsk-spinoff-haleon-is-said-to-explore-sale-of-chapstick-brand?leadSource=uverify%20wall#selection-3471.0-3471.74|work=Bloomberg|access-date=28 FebruaryFebruari 2023}}</ref>

Kesehatan mulut menyumbang 28,5 persen dari pendapatan pada tahun 2021.<ref name="gsk1">{{Cite web|title=Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon|url=https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/|website=GSK|publisher=GSK|access-date=10 JuneJuni 2022|archive-date=2023-03-29|archive-url=https://web.archive.org/web/20230329162356/https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/|dead-url=no}}</ref>

Aset kotor berjumlah lebih dari £45 miliar pada 31 Maret 2022.<ref name="gsk12">{{Cite web|title=Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon|url=https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/|website=GSK|publisher=GSK|access-date=10 JuneJuni 2022|archive-date=2023-03-29|archive-url=https://web.archive.org/web/20230329162356/https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/|dead-url=no}}</ref>

* Advil ( [[Ibuprofen]] )

Pada 2022, Pfizer memiliki 32 persen saham Haleon, sedangkan GSK mempertahankan 13 persen saham.<ref name="reuters12">{{Cite news|last=Donnellan|first=Aimee|date=9 JuneJuni 2022|title=GSK castoff starts life with target on its back|url=https://www.reuters.com/breakingviews/gsk-castoff-starts-life-with-target-its-back-2022-06-09/|work=[[Reuters]]|access-date=10 JuneJuni 2022|archive-date=2022-09-22|archive-url=https://web.archive.org/web/20220922114359/https://www.reuters.com/breakingviews/gsk-castoff-starts-life-with-target-its-back-2022-06-09/|dead-url=no}}</ref>